Centauri scoops up to £945K award to develop innovative antibiotics
Project will use the company's Alphamer technology, which is based on 'programmable immunity' in which chemically synthesized molecules redirect naturally occurring antibodies to selected pathogens to fight the infection.
Centauri Therapeutics has been awarded up to £945,000 under Innovate UK’s Biomedical Catalyst (BMC) programme. Alongside backing from the company’s investors, this award from the UK’s innovation agency will co-fund research focused on antimicrobial resistance. The project aims to generate a clinical candidate drug against Gram-negative bacteria, which are a major cause of mortality in hospital-acquired pneumonias, using the company’s Alphamer technology.
Centauri plans to develop an innovative treatment for patients suffering from infections caused by resistant bacteria. Using the company’s Alphamer drug mechanism, chemically synthesised molecules will redirect pre-existing antibodies to pathogens in a specific manner that elicits an immune response. This immune response will mediate destruction of the bacteria to clear the infection, while working in conjunction with existing antibiotics to reduce the dose and duration of therapy. Unlike traditional vaccines, this approach aims to treat infected patients and has the potential to elicit a broader immune response than monoclonal antibodies alone.
The Alphamer technology is based on 'programmable immunity' in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection.
Dr Mike Westby, Director and CEO of Centauri Therapeutics, commenting on the award said: “The lack of new antibiotics combined with increasing incidence of bacterial resistance in the clinic has been termed ‘the perfect storm’ and there is an urgent need for innovative methods and efficacious therapies. The BMC Award is a significant recognition of Centauri’s scientific expertise and demonstrates the UK government’s confidence in our team’s ability to combat antibacterial resistance and deliver novel treatments for patients.”
Total costs for the project titled ‘Optimisation of antibody recruiting molecules as immunotherapeutics’ are estimated at £1.35 million. The co-funding from Innovate UK will cover up to 70% of this, with Centauri’s investors supporting the remaining 30% of the project costs over a 2-year period.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance